VOR

Vor Biopharma Inc. (VOR) | Rumor.io

Vor Biopharma

VOR

Attention (50-day avg)0%

Attention rank (50-day avg)#4,023

Bullish sentiment (50-day avg)100%

Price to earnings ratio0.1

Market capitalization992.1M

Earnings per share180.6

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-696M

Social

What share of all stock conversation is about VOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Feb 23

$VOR is identified as being in a strong position, "curling up" out of a base, with one post noting "cold vision, real substance".
Vor Biopharma Inc. is seen as offering "unreal value" with one post calling it a "free game".
The stock is noted as being in a favorable technical position, with multiple posts observing it "curling up" or rising out of a base.

Generated by AI

Sentiment

Of the messages about VOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	75.64% -9.95
Bearish	0%	0%	0% 0	24.36% +9.95

Bullish· Dec 30

$VOR is showing a clear "Smart Money" buy signal, with RA Capital leading a $150M private placement, indicating strong validation.
The stock has a history of trading up and down in a predictable pattern, with a potential sharp rise and break above $14.75, and a high of $16 with increasing volume.
The stock has strong fundamentals, with a recent $22.9M quarterly revenue, indicating a change in tone and making it a more attractive investment opportunity.

Bearish· Dec 9

The price of $VOR is likely to drop back to the $10 range due to institutions selling their positions.
The company's bio stock is considered "hilarious" by some, implying a lack of seriousness or potential for significant losses.
Short sellers are actively targeting $VOR, with some aiming for a price below $10.65.

Generated by AI

Topics

Of the messages about VOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	16.58%
Analysts	—	—	—	15.48%
Announcements	—	—	—	55.68%
Controversies	—	—	—	4.92%
Earnings	—	—	—	0%
Macro	—	—	—	7.34%

Announcements· Jun 26

Vor Biopharma Inc. ($VOR) has acquired a late-stage autoimmune asset from RemeGen, with a deal valued at $4B in biobucks.
The company has also secured $175M in financing to advance its clinical pipeline and has appointed Jean-Paul Kress as its new CEO.
Vor Bio has entered into an exclusive global license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein, with potential regulatory and commercial milestones exceeding $4B.

Technical Analysis· Jun 26

The author is watching $VOR and believes a move over $1.20 could provide a nice opportunity to scalp to $1.25, $1.32, then $1.40.
The author believes that if $VOR breaks below $1.10, it's done, while a break above $1.2 could lead to an explosion.
The author thinks that $VOR's chart is looking healthy, with possible volume and a 1.50 touch before 7am, and notes that a strong bounce off vwap is needed.

Generated by AI

Community

Of the messages about VOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	48.54%
Newcomers	0%	0%	0%	51.46%

Regulars· Aug 22

The stock of Vor Biopharma Inc. has seen a significant surge of 250% in the past week, according to Yahoo Finance.
This increase in value is likely due to the company's progress in its pipeline, which has been a point of interest for regular participants in the asset's discussion.
The focus of the discussion among regular participants is on the company's pipeline and its potential to drive future growth, rather than on broader market trends or external factors.

Newcomers· Dec 30

Newcomers are focusing on a strong "Smart Money" buy signal for $VOR, citing a $150M private placement led by RA Capital as validation.
Some newcomers are cautious, viewing the current trend as a "Dead Cat Bounce" in a bear market, and require a reclaim of the $28 level to consider it a genuine trend reversal.
Others are warning that the pump is a fool's errand, as $VOR is still trading 50% below the 50-Day MA, and until it surpasses $28, it's just a bearish sign.

Generated by AI

News

Stifel reiterates Vor Biopharma stock rating on telitacicept potential

1d agoInvesting.com

Vor Biopharma at Stifel 2026 forum: telitacicept pushes dual path

6d agoInvesting.com

Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR)

Vor Biopharma is advancing telitacicept globally, leveraging strong Chinese clinical evidence and a robust liquidity position. Read why VOR stock is a buy.

12d agoSeeking Alpha

Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push

20d agoInvesting.com

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Topline results from UPSTREAM MG’s 24-week primary endpoint remain on track for first half of 2027 Global Phase 3 ocular myasthenia gravis (oMG) registrational trial, UPSTREAM oMG, broadens telitacicept development across the myasthenia gravis (MG) spectrum; first patient dosing anticipated in the first half of 2027 BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the comple

22d agoYahoo Finance UK

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on September 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 83,600 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 17,900 shares of Vor Bio’s common stock to 6 newly hired employees. The

25d agosg.finance.yahoo.com

Also Discussed

Investors talking about VOR also mention

#	Name	Attention
1	MKDWELL Tech Inc.MKDW	0%+0
2	Wag! Group Co.PET	0%0
3	Wang & Lee Group Inc.WLGS	0%0
4	Zenas BioPharma, Inc.ZBIO	0%0
5	Janux Therapeutics, Inc.JANX	0%0
6	Edgewise Therapeutics Inc.EWTX	0%new
7	HSPO - Horizon Space Acquisition I Corp. Ordinary Shares	——
8	Ostin Technology Group Co., Ltd.OST	0%0
9	Atif Holdings Ltd.ZBAI	0%0
10	Globavend Holdings LimitedGVH	0%0

Vor Biopharma Inc.

Healthcare
Biotechnology

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its lead program is telitacicept, a dual-target fusion protein designed to regulate abnormal B-cell activity that drives autoantibody-mediated conditions. The company’s current development and commercialization efforts center on autoimmune indications such as generalized myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren’s disease, and IgA nephropathy. Vor Biopharma works on advancing this therapy through clinical development and broader market access, positioning its platform within the specialized immunology and biopharmaceutical segments. Headquartered in Cambridge, Massachusetts, Vor Biopharma plays a role in the market by addressing serious chronic diseases with targeted biologic treatment approaches.

Website

Location

500 Boylston Street

Boston, MA, 02116

United States

Social

What share of all stock conversation is about VOR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Feb 23

$VOR is identified as being in a strong position, "curling up" out of a base, with one post noting "cold vision, real substance".
Vor Biopharma Inc. is seen as offering "unreal value" with one post calling it a "free game".
The stock is noted as being in a favorable technical position, with multiple posts observing it "curling up" or rising out of a base.

Generated by AI

Sentiment

Of the messages about VOR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% 0	75.64% -9.95
Bearish	0%	0%	0% 0	24.36% +9.95

Bullish· Dec 30

$VOR is showing a clear "Smart Money" buy signal, with RA Capital leading a $150M private placement, indicating strong validation.
The stock has a history of trading up and down in a predictable pattern, with a potential sharp rise and break above $14.75, and a high of $16 with increasing volume.
The stock has strong fundamentals, with a recent $22.9M quarterly revenue, indicating a change in tone and making it a more attractive investment opportunity.

Bearish· Dec 9

The price of $VOR is likely to drop back to the $10 range due to institutions selling their positions.
The company's bio stock is considered "hilarious" by some, implying a lack of seriousness or potential for significant losses.
Short sellers are actively targeting $VOR, with some aiming for a price below $10.65.

Generated by AI

Topics

Of the messages about VOR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	16.58%
Analysts	—	—	—	15.48%
Announcements	—	—	—	55.68%
Controversies	—	—	—	4.92%
Earnings	—	—	—	0%
Macro	—	—	—	7.34%

Announcements· Jun 26

Vor Biopharma Inc. ($VOR) has acquired a late-stage autoimmune asset from RemeGen, with a deal valued at $4B in biobucks.
The company has also secured $175M in financing to advance its clinical pipeline and has appointed Jean-Paul Kress as its new CEO.
Vor Bio has entered into an exclusive global license agreement with RemeGen to develop and commercialize telitacicept, a novel dual-target fusion protein, with potential regulatory and commercial milestones exceeding $4B.

Technical Analysis· Jun 26

The author is watching $VOR and believes a move over $1.20 could provide a nice opportunity to scalp to $1.25, $1.32, then $1.40.
The author believes that if $VOR breaks below $1.10, it's done, while a break above $1.2 could lead to an explosion.
The author thinks that $VOR's chart is looking healthy, with possible volume and a 1.50 touch before 7am, and notes that a strong bounce off vwap is needed.

Generated by AI

Community

Of the messages about VOR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	48.54%
Newcomers	0%	0%	0%	51.46%

Regulars· Aug 22

The stock of Vor Biopharma Inc. has seen a significant surge of 250% in the past week, according to Yahoo Finance.
This increase in value is likely due to the company's progress in its pipeline, which has been a point of interest for regular participants in the asset's discussion.
The focus of the discussion among regular participants is on the company's pipeline and its potential to drive future growth, rather than on broader market trends or external factors.

Newcomers· Dec 30

Newcomers are focusing on a strong "Smart Money" buy signal for $VOR, citing a $150M private placement led by RA Capital as validation.
Some newcomers are cautious, viewing the current trend as a "Dead Cat Bounce" in a bear market, and require a reclaim of the $28 level to consider it a genuine trend reversal.
Others are warning that the pump is a fool's errand, as $VOR is still trading 50% below the 50-Day MA, and until it surpasses $28, it's just a bearish sign.

Generated by AI

Vor Biopharma

Social

Feb 23

Bullish· Dec 30

Bearish· Dec 9

Announcements· Jun 26

Technical Analysis· Jun 26

Regulars· Aug 22

Newcomers· Dec 30

Stifel reiterates Vor Biopharma stock rating on telitacicept potential

Vor Biopharma at Stifel 2026 forum: telitacicept pushes dual path

Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR)

Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Vor Biopharma Inc.

Company Information

Location

Stifel reiterates Vor Biopharma stock rating on telitacicept potential

Vor Biopharma at Stifel 2026 forum: telitacicept pushes dual path

Vor Biopharma: A Funded Replication Story With Franchise Potential (NASDAQ:VOR)

Vor Biopharma at Citigroup’s biopharma back to school summit: pipeline push

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Also Discussed

Social

Feb 23

Bullish· Dec 30

Bearish· Dec 9

Announcements· Jun 26

Technical Analysis· Jun 26

Regulars· Aug 22

Newcomers· Dec 30